Physician profile
Charles E Williams
NPI 1518922822
$1,567.53
in general payments reported to CMS, 2019-2025
15 companies · $195 in 2025
The $195 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $192 · 2020: $327 · 2021: $176 · 2022: $107 · 2023: $265 · 2024: $306 · 2025: $195.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $766.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $765.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $469.58 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $388.99 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $231.35 | 2020-2025 | |
| Exact Sciences Corporation | $100.83 | 2024-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $71.45 | 2024 | Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $61.65 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $52.10 | 2020-2021 | |
| Amgen INC. | $40.78 | 2023-2024 | Krystexxa, Otezla, Repatha |
| Lilly USA, LLC | $32.12 | 2022 | |
| Sanofi-Aventis U.S. LLC | $24.78 | 2024 | |
| Abbvie INC. | $22.14 | 2023 | Ubrelvy |
| Bayer Healthcare Pharmaceuticals INC. | $20.64 | 2023 | |
| Sanofi Pasteur INC. | $19.60 | 2022 | |
| Novartis Pharmaceuticals Corporation | $16.59 | 2023 | |
| Vistapharm, INC. | $14.93 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.